EDGAR Filing Documents for 0001564590-20-006564

Form 8-K - Current report:

SEC Accession No. 0001564590-20-006564

Filing Date

2020-02-26

Accepted

2020-02-26 06:50:27

Documents

Period of Report

2020-02-26

Items

Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	amrx-8k_20200226.htm iXBRL	8-K	37770
2	EX-99.1	amrx-ex991_15.htm	EX-99.1	4019718
3	GRAPHIC	gq3pffqfpdhl000001.jpg	GRAPHIC	2059
	Complete submission text file	0001564590-20-006564.txt		4293447

Data Files

Seq	Description	Document	Type	Size
4	XBRL TAXONOMY EXTENSION SCHEMA	amrx-20200226.xsd	EX-101.SCH	5960
5	XBRL TAXONOMY EXTENSION LABEL LINKBASE	amrx-20200226_lab.xml	EX-101.LAB	18707
6	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE	amrx-20200226_pre.xml	EX-101.PRE	11167
10	EXTRACTED XBRL INSTANCE DOCUMENT	amrx-8k_20200226_htm.xml	XML	3432

Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807

Business Address (908) 947-3120

Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38485 | Film No.: 20653261
SIC: 2834 Pharmaceutical Preparations